Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer

被引:105
作者
Jiang, Z. F. [1 ]
Wang, M. [2 ]
Xu, J. L. [3 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 1, Natl Key Clin Specialist Construct Programs China, Dept Resp Med, Jixi Rd 218, Hefei 230022, Anhui, Peoples R China
[2] Anhui Chest Hosp, Dept Resp Med, Jixi Rd 397, Hefei 230022, Anhui, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai 200030, Peoples R China
关键词
Lung cancer; TK1; CEA; CYFRA21-1; NSE; CLINICAL UTILITY; TUMOR-MARKERS; BREAST; COMBINATION; PROGNOSIS; BIOMARKER; BLOOD; RISK;
D O I
10.1016/j.lfs.2017.12.020
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aims: Thymidine kinase 1 (TK1) is a tumor biomarker in human malignancies. The purpose of this study was to evaluate the diagnostic efficiency of this marker for lung cancer using the combined analysis of carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), neuron specific enolase (NSE) and TK1. Main methods: From 2013 to 2014, 147 patients with lung cancer and 228 patients with lung benign diseases who were admitted to our hospital were reviewed. Peripheral blood samples were collected for the detection of TK1, CEA, CYFRA21-1 and NSE. The diagnostic value of each marker was analyzed using receiver operating characteristic (ROC) curves and logistic regression equations. Key findings: The serum levels of TK1, CEA, CYFRA21-1 and NSE were significantly higher than those in patients with lung benign diseases (all P < 0.05). The TK1 concentration was dependent on TNM stage (P=0.005). The ROC curve analyses showed that the diagnostic value of TK1 combined with CEA, CYFRA21-1 and NSE in lung cancer was significantly higher than that of each biomarker alone (all P < 0.0001). In addition, TK1 combined with CEA, CYFRA21-1, or NSE could also improve the diagnosis of the squamous cell carcinoma, adenocarcinoma and small cell lung cancer subtypes, respectively.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 29 条
[1]   Serum Thymidine Kinase 1 Activity in Solid Tumor (Breast and Colorectal Cancer) Patients Treated With Adjuvant Chemotherapy [J].
Bolayirli, M. ;
Papila, C. ;
Korkmaz, G. G. ;
Papila, B. ;
Aydogan, F. ;
Karatas, A. ;
Uzun, H. .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2013, 27 (03) :220-226
[2]   Thymidine kinase as a proliferative marker:: Clinical relevance in 1,692 primary breast cancer patients [J].
Broët, P ;
Romain, S ;
Daver, A ;
Ricolleau, G ;
Quillien, V ;
Rallet, A ;
Asselain, B ;
Martin, PM ;
Spyratos, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2778-2787
[3]  
Chen F, 2015, INT J CLIN EXP MED, V8, P11295
[4]   Epidemiology of lung cancer in China [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Zeng, Hongmei ;
Zhang, Siwei .
THORACIC CANCER, 2015, 6 (02) :209-215
[5]   Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings [J].
Chen, Yan ;
Ying, Mingang ;
Chen, YanSong ;
Hu, Minhua ;
Lin, Yingying ;
Chen, Dedong ;
Li, Xiaoli ;
Zhang, Ming ;
Yun, Xia ;
Zhou, Ji ;
He, Ellen ;
Skog, Sven .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) :359-368
[6]   Serological Thymidine Kinase 1 is a Biomarker for Early Detection of Tumours-A Health Screening Study on 35,365 People, Using a Sensitive Chemiluminescent Dot Blot Assay [J].
Chen, Zhi Heng ;
Huang, Shou Qing ;
Wang, Yande ;
Yang, Ai Zhen ;
Wen, Jian ;
Xu, Xiao Hong ;
Chen, Yan ;
Chen, Qu Bo ;
Wang, Ying Hong ;
He, Ellen ;
Zhou, Ji ;
Skog, Sven .
SENSORS, 2011, 11 (12) :11064-11080
[7]  
Chen ZH, 2008, ANTICANCER RES, V28, P3897
[8]  
Gaspar MJ, 2008, ANTICANCER RES, V28, P2947
[9]   DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES [J].
GOLD, P ;
FREEDMAN, SO .
JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (03) :439-+
[10]  
Hallek M, 1999, BLOOD, V93, P1732